Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585493 | 1.00 | CYP3A4 (0.46) | CYP3A4LMNAGABRA1TSHRGABRG2 | |
| Piperazine SCHEMBL11121855 | 1.00 | CYP3A4 (0.46) | CYP3A4LMNAGABRA1TSHRGABRG2 | |
| Aziridine SCHEMBL4605466 | 0.96 | — | — | |
| Pyrrolidine SCHEMBL8652906 | 0.87 | ALDH1A1 (0.47) | CYP3A4LMNAGABRA1TSHRGABRG2 | |
| SCHEMBL28163184 | 0.87 | LMNA (0.36) | CYP3A4LMNAGABRA1TSHRGABRG2 | |
| Piperazine SCHEMBL27671947 | 0.86 | LMNA (0.46) | CYP3A4LMNAGABRA1TSHRGABRG2 | |
| Piperazine SCHEMBL27330293 | 0.86 | LMNA (0.46) | CYP3A4LMNAGABRA1TSHRGABRG2 | |
| Azetidine SCHEMBL29252035 | 0.86 | — | — | |
| Azetidine SCHEMBL5748083 | 0.86 | CYP3A4 (0.39) | CYP3A4LMNAGABRA1TSHRGABRG2 | |
| Sulfuric Acid SCHEMBL8300104 | 0.85 | TSHR (0.50) | CYP3A4LMNAGABRA1TSHRGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014037886-A1 | PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2014-03-13 | — | — | WO | claimed |
| CN-101068798-B | Salts and crystals of 1-cyclopropylmethyl-4- [2- (3,3,5, 5-tetramethylcyclohexyl) phenyl ] piperazine | EISAI R&D MAN CO LTD | 2010-05-12 | — | — | CN | claimed |
| CN-101068798-A | Salts and crystals of 1-cyclopropylmethyl-4- [ 2- (3,3,5, 5-tetramethylcyclohexyl) phenyl ] piperazine | EISAI R&D MAN CO LTD (JP) | 2007-11-07 | — | — | CN | claimed |
| CN-1089086-C | Luminandide medicine | MILLS RANDELL L (US) | 2002-08-14 | — | — | CN | claimed |
| CN-119367311-A | Doxazosin mesylate sustained release tablet and preparation method thereof | 南京易亨制药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-117777116-A | Preparation method of high-purity doxazosin mesylate F crystal form | 合肥立方制药股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116133688-A | Multilayer inhalation medicine | 迈兰制药英国有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-110283162-B | Epidermal growth factor receptor inhibitor and application thereof | 辽宁大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-113750063-A | Solid preparation of piperazine isethionate cetirizine and preparation method thereof | 江苏食品药品职业技术学院 | 2021-12-07 | — | — | CN | disclosed |
| CN-108558865-B | Derivative taking pyrido [2,3-d ] pyrimidine structure as mother nucleus, and preparation method and application thereof | 辽宁大学 | 2021-06-01 | — | — | CN | disclosed |
| US-10695449-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| CN-110325533-A | INHIBITORS OF THE MENIN-MLL INTERACTION | 生命医药有限责任公司 | 2019-10-11 | — | — | CN | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| CN-1301149-A | Lofuridine tablets | UPJOHN CO (US) | 2001-06-27 | — | — | CN | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
| CN-1221398-A | Mannitol and its preparation | BAYER AG (DE) | 1999-06-30 | — | — | CN | disclosed |
| CN-87107548-A | Strengthen the compositions of transdermal flux | — | 1988-05-11 | — | — | CN | disclosed |
| CN-87104918-A | The drug-containing fibers of controllable release | — | 1988-01-27 | — | — | CN | disclosed |
| EP-0034284-B1 | PIPERAZINE DERIVATIVE, PROCESSES FOR PREPARING THE SAME AND THERAPEUTIC COMPOSITIONS CONTAINING IT | Tanabe Seiyaku Co., Ltd. (JP) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695449-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | CYP3A4 2708/4885LMNA 3906/4885GABRA1 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.